Paper · 7531365
Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
Uckun FM and 8 others. Science, 1995. Cited by 239 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Papers, record 7531365. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7531365
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, CD | Major topic |
| Antigens, Differentiation, B-Lymphocyte | Major topic |
| Immunoconjugates | Major topic |
| Isoflavones | Major topic |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Major topic |
| Protein-Tyrosine Kinases | Major topic |
| Animals | |
| Antibodies, Monoclonal | |
| Antigens, CD19 | |
| Apoptosis | |
| DNA Damage | |
| DNA, Neoplasm | |
| Genistein | |
| Leukemic Infiltration | |
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | |
| Mice | |
| Mice, SCID | |
| Tissue Distribution | |
| Tumor Cells, Cultured |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA-42111 | NCI NIH HHS | United States | R01CA042111 | PubMed and NIH | NIH RePORTER |
| CA-42633 | NCI NIH HHS | United States | R01CA042633 | PubMed and NIH | NIH RePORTER |
| CA-51425 | NCI NIH HHS | United States | R01CA051425 | PubMed and NIH | NIH RePORTER |
| R29CA042111 | NIH | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 239 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37,838,981 | Molecular pharmacology of the onco-TRP channel TRPV6. | Channels (Austin) | 2023 | https://conductscience.org/library/papers/37838981 | PubMed |
| 37,457,582 | The influence of COVID-19 on colorectal cancer was investigated using bioinformatics and systems biology techniques. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/37457582 | PubMed |
| 37,160,865 | Structural mechanism of human oncochannel TRPV6 inhibition by the natural phytoestrogen genistein. | Nat Commun | 2023 | https://conductscience.org/library/papers/37160865 | PubMed |
| 36,936,272 | The role of isoflavones in augmenting the effects of radiotherapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/36936272 | PubMed |
| 36,091,808 | Discovery of genistein derivatives as potential SARS-CoV-2 main protease inhibitors by virtual screening, molecular dynamics simulations and ADMET analysis. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36091808 | PubMed |
| 35,815,271 | Genistein: Therapeutic and Preventive Effects, Mechanisms, and Clinical Application in Digestive Tract Tumor. | Evid Based Complement Alternat Med | 2022 | https://conductscience.org/library/papers/35815271 | PubMed |
| 32,332,902 | Phytochemical analysis and biological activities of in vitro cultured Nidularium procerum, a bromeliad vulnerable to extinction. | Sci Rep | 2020 | https://conductscience.org/library/papers/32332902 | PubMed |
| 30,292,138 | Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies. | Mol Ther Nucleic Acids | 2018 | https://conductscience.org/library/papers/30292138 | PubMed |
| 25,892,662 | Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. | Semin Cancer Biol | 2015 | https://conductscience.org/library/papers/25892662 | PubMed |
| 24,910,947 | CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells. | Integr Biol (Camb) | 2014 | https://conductscience.org/library/papers/24910947 | PubMed |
1 to 10 of 34
See all 34 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| TXK | 7,294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7531365
GET https://conductscience.org/api/papers/v1/7531365/cited_by?page=2